Svmuu reports that Ark Invest has purchased a total of 41,904 shares of Circle stock across three ETFs, valued at $5.5 million. This marks its first purchase of Circle since March 24. Currently, Circle's market value in ARKK is $306.5 million, in ARKW is $82.3 million, and in ARKF is $56 million.
Circle released its first-quarter financial report, with total revenue reaching $694 million, up 20% year-over-year, while net profit fell to $55 million. On-chain USDC transaction volume reached $21.5 trillion, with a circulating supply of $77 billion. Circle's stock price rose 15.91% to $131.76.
Ark Invest Buys $5.5 Million in Circle Stock
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
3
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
4
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
5
Israeli West Bank Settler Tells BBC Attacks on Palestinians Are Justified as Revenge, Equating One Jewish Life to "10 Million" Palestinians
-
6
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
7
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
8
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
9
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
10
Analysis: Vanguard Small-Cap Growth ETF (VBK) up 21% YTD 2026, Outperforming Large-Cap Growth ETF (VONG) at 0.3% YTD
Markets Today
Recommended Reading






